A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

ClinicalTrials.gov ID: NCT04245839

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04245839. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 3:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Open-label, Single Arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL. The study will be conducted in compliance with the International Council on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This study is divided into three periods: * Pretreatment, which consists of screening assessments, leukapheresis and the Pretreatment evaluation; * Treatment, which starts with the administration of lymphodepleting (LD) chemotherapy and continues through JCAR017 administration at Day 1 with follow-up through Day 29; * Posttreatment, which includes follow-up assessments for disease status and safety for 5 years.

Study identification

NCT ID: NCT04245839
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Celgene; Industry
Enrollment: 276 participants

Conditions and interventions

Conditions

Lymphoma, Non-Hodgkin

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 14, 2020 (Actual)
Primary completion: Sep 30, 2031 (Estimated)
Completion: Sep 30, 2031 (Estimated)
Last update posted: Nov 5, 2025

2020 – 2031

United States locations

U.S. sites: 23
U.S. states: 19
U.S. cities: 21

Facility	City	State	ZIP	Site status
Local Institution - 111	Santa Monica	California	90095	—
Local Institution - 107	Aurora	Colorado	80045	—
Local Institution - 105	New Haven	Connecticut	06520	—
Local Institution - 103	Chicago	Illinois	60611	—
Local Institution - 109	Niles	Illinois	60714	—
Local Institution - 122	Iowa City	Iowa	52242	—
Local Institution - 124	Wichita	Kansas	67124	—
Local Institution - 102	Baltimore	Maryland	21201	—
Local Institution - 100	Boston	Massachusetts	02114	—
Local Institution - 101	Boston	Massachusetts	02215	—
Local Institution - 127	Detroit	Michigan	48201	—
Local Institution - 123	Morristown	New Jersey	07960	—
Local Institution - 116	New York	New York	10021	—
Local Institution - 110	Charlotte	North Carolina	28204	—
Local Institution - 112	Cleveland	Ohio	44195	—
Local Institution - 114	Portland	Oregon	97213	—
Local Institution - 117	Philadelphia	Pennsylvania	19104	—
Local Institution - 113	Sioux Falls	South Dakota	57105	—
Local Institution - 121	Dallas	Texas	75230-2510	—
Local Institution - 104	Houston	Texas	77030	—
Local Institution - 119	Houston	Texas	77030	—
Local Institution - 115	Charlottesville	Virginia	22903	—
Local Institution - 108	Seattle	Washington	98109	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04245839, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 5, 2025 · Synced Nov 13, 2026